PLT VASP/P2Y12

Back to list

default
Reference
7014
Status
CE
Sample
30 µL citrated  whole blood.
Quantity
10 tests
Detection
Fluorescent
Application
Flow Cytometry Kits
Form

- Diluent
- PGE1
- PGE1 + ADP
- Fixative agent
- Anti VASP-P MAb
- Negative isotypic control
- Staining reagent FITC conjugated + counter staining reagent (CD61-PE)

In the test conditions, VASP (Vasodilator Stimulated Phosphoprotein) phosphorylation correlates with the P2Y12 receptor inhibition, whereas its non-phosphorylation state correlates with the active form of P2Y12 receptors. Blood sample is first incubated with PGE1 alone or PGE1+ADP. After a cellular permeabilization, VASP under its phosphorylated state is labeled by indirect no wash immunofluorescence using a specific monoclonal antibody. Dual color flow cytometry analysis allows to compare the two tested conditions and to evaluate for each sample the capacity of ADP to inhibit VASP phosphorylation.
Date Document Name Download
01/03/2015 Package insert PLT VASP P2Y12 DE (500.52 KB)
EN (175.26 KB)
ES (543.38 KB)
FR (243.07 KB)
IT (526.13 KB)
PT (530.45 KB)
08/06/2010 Flyer PLT VASP P2Y12 EN (592.82 KB)
Author Title Year of edition Review
Barragan P et al.
Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation
2003
Cathet Cardiovasc Intervent
Aleil B et al.
Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
2005
J Thromb Haemost
Aleil B et al.
High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease
2005
Thromb Haemost.
Aleil B and Gachet C
Inter-individual variability in the response to clopidogrel
2005
Archives des Maladies du Coeur et des Vaisseaux
Gurbel PA et al.
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study
2005
J Am Coll Cardiol
Montalescot G et al.
A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes
2006
JACC
Gilart M.et al.
Influence of omeprazol on the anti platelet action of clopidogrel associated to aspirin
2006
J Thromb Haemost
Bura A et al.
Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healty subjects
2006
J Thromb Haemost
Hulot JS et al.
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
Blood
Cauwenberghs et al.
Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation
2006
Transfusion
Pampuch et al.
Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor
2006
Thromb Haemost.
Gurbel PA and Tantry U
Drug insight : clopidogrel responsiveness
2006
Nat Clin Pract Cardiovasc Med
Aleil B et al.
Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases
2007
J Thromb Haemost
Angiolilo DJ et al.
Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetis mellitus and coronary artery disease
2007
Circulation
van Werkum et al.
The flow cytometric VASP assay can be used to determined the effectiveness of clopidogrel in patients treated with Abciximab
2007
J Thromb Haemost
Cuisset T et al.
Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome
2007
Thromb Haemost.
Mueller Tet al.
Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods"
2007
Thromb Res
Cuisset T. et al.
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome
2007
Thromb Res
Bonello L et al.
VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events
2007
J Thromb Haemost
Cattaneo M et al.
Platelet P2 receptors: old and new targets for antithrombotic drugs
2007
Cardiovascular Therapy
Gurbel PA et al.
Assessment of clopidogrel responsiveness : measurements of maximum platelet agreggation, final platelet agreggation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients
2007
Thromb Res
Schumacher WA et al.
Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel
2007
J Pharmacol Exp Ther.
De Gaetano and Cerletti.
Platelet function, antiplatelet therapy and clinicla outcomes : to test or not to test ?
2007
J Thromb Haemost
Paniccia R et al.
Different methodologies for evaluating the effect of clopidogrel on platelet function in high isk coronary artery disease patients
2007
J Thromb Haemost
Dropinski et al.
The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin
2007
Thromb Haemost.
Fontana P et al.
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopicogrel responsiveness
2007
Thromb Haemost.
Morel O et al.
Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis
2007
Thromb Haemost.
Frere C et al.
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome
2007
Thromb Haemost.
Gurbel PA et al.
Platelet function monitoring in patients with coronary artery disease
2007
JACC
Blindt R et al.
The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis
2007
Thromb Haemost.
Eli Lev et al.
Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease
2007
Am Heart J
Schäfer A et al.
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ?
2007
Thromb Haemost.
Wiviott SD et al.
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Circulation
Wallentin L et al.
Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2008
European Heart Journal
Sbrana S et al.
Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation
2008
Cytometry Part B
Gilard M. et al.
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
2008
J. Am. Coll. Cardiol.
Gurbel PA et al.
Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
2008
J. Am. Coll. Cardiol.
Frere C et al.
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
2008
Am J Cardiol.
Angiolillo DJ et al.
Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition on
Standard Dose Treatment
2008
Am J Cardiol.
Bonello L et al.
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study
2008
J. Am. Coll. Cardiol.
Jakubowski J et al.
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
2008
Thromb Haemost.
Yano Y et al.
Determinants of thrombin generation,fibrinolytic activity, and endothelial dysfunction
in dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow’s triad
2008
Eur Heart J.
Umemura K et al,
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects
2008
J Thromb Haemost
Bonello L et al,
A threshold of platelet reactivity for ischaemic events?
2008
Eur Heart J.
Bonello L et al,
Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention
2008
Thromb Res
Michelson A et al.
P2Y12 Antagonism: Promises and Challenges
2008
ATVB
Angiolillo DJ et al.
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
2008
Eur Heart J.
Schäfer A et al.
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay
2008
Thromb Haemost
Siller-Matula JM et al.
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
2008
J. Am. Coll. Cardiol.
Morel O et al.
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
2008
Thromb Haemost
Djukanovic N. et al.
Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors
2008
J Pharmacol Sci
De Miguel A et al.
Clinical implications of clopidogrel resistance
2008
Thromb Haemost.
Weber AA et al.
Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs
2008
Herz
Aleil B al.
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention"
2008
J Am Coll Cardiol Intv
Erlinge D et al.
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
2008
J. Am. Coll. Cardiol.
Cayla G et al.
Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes
2008
Arch Cardiovasc Dis.
Bonello L et al.
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
2009
Am J Cardiol.
Lortie E. et al.
Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits
2009
Thromb Res
Siller-Matula JM et al.
The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
2009
Thromb Res
Bonello L et al.
Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines
2009
Heart
Hogberg C. et al .
Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment
2009
Thrombosis Journal
Cuisset T et al.
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response
2009
Thromb Res.
Varenhorst C et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
2009
Eur Heart J
Motovska Z et al.
High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial
2009
Blood Coagul Fibrinolysis
Michelson A. et al
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
2009
European Heart Journal
Cuisset T et al.
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronay syndrome
2009
EuroIntervention
Aleil B. et al.
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
2009
J Thromb Haemost
Siller-Matula JM et al.
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
2009
Am Heart J
Cuisset T et al.
Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose
2009
J. Am. Coll. Cardiol.
Alström U et al.
Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery
2009
Thromb Res
Siller-Matula JM et al.
Cross validation of the Multiple Electrode Aggregometry
2009
Thromb Haemost.
Gremmel T et al.
Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation
2009
Thromb Haemost.
James S et al.
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Am Heart J
Gurbel PA and Tantry U.
Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease
2009
Curr Treat Op Cardio Med
Frere C et al.
CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome
2009
J Thromb Haemost.
Motovska Z et al.
Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures
2009
Thrombosis J
Motovska Z et al.
Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness
2010
Int J Cardiol.
Palmerini T. et al,
A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study
2010
Thromb Res
Bonello L et al.
Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism
2010
Int J cardiol.
Bonello L et al.
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients
2010
Thromb Res.
von Beckerath N et al.
Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry
2010
Blood Coagulation and Fibrinolysis
Gurbel PA et al.
The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients
2010
J Thromb Haemost.
Bellemain-Appaix A et al.
Slow Response to Clopidogrel Predicts Low Response
2010
J. Am. Coll. Cardiol.
Metzmer H et al.
Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring
2010
Eur J Anaesthesiol.
Cuisset T et al.
Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
2010
Archives of Cardiovascular Disease
Gurbel PAet al.
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study
2010
Circulation
Small DS et al.
Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial
2010
Clin Ther.
Flierl U et al.
The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats
2010
Thromb Res
Bouman HJ et al.
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
2010
J Thromb Haemost.
Gajos G et al.
Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
2010
J. Am. Coll. Cardiol.
El Ghannudi S
Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty
2010
J Am Coll Cardiol Intv
Bonello L et al.
Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism
2010
J. Am. Coll. Cardiol.
Delavenne X et al.
Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?
2010
J Thromb Haemost. 
Aradi D et al.
Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition
2010
Platelets
Zighetti ML et al.
Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP
2010
J Thromb Haemost. 
Bonello L et al.
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
2010
J. Am Coll Cardiol.
Storey RF et al.
Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
2010
J. Am. Coll. Cardiol.
Angiolillo DJ et al.
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study
2010
J. Am. Coll. Cardiol.
Bonello L et al.
Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury,assessed by CEC measurement
2010
J. Am. Coll. Cardiol.
Bjellanda TW et al.
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest
2010
Resuscitation
Fu Q et al.
Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting
2010
Int Heart J.
Fontana P et al.
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study
2010
J Thromb Haemost.
Ferreiro JL et al.
Pharmacodynamic effects of concomitant versus stagerred clopidogrel and omeprazole intake
2010
Circ Cardiovasc Interv.
Tantry U et al.
First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies
2010
Circ Cardiovasc Genet.
Osmancik P et al.
A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction"
2010
Catheter Cardiovasc Interv.
Kalantzi KI et al.
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory
response in patients with acute coronary syndromes
2011
J Thromb Haemost.
Petrucci G et al.
Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors
2011
JPET
Morel O et al.
Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel
2011
J. Am. Coll. Cardiol.
Ueno M et al.
Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease
2011
Thromb Haemost
Angiolillo DJ et al.
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
2011
Thromb Haemost
Freynhofer MK et al.
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction
of postprocedural major adverse cardiovascular events
2011
Thromb Haemost
Motovska Z et al.
Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking
2009
J Cardiovasc Pharmacol
Mani H. et al.
Platelet function testing in hirudin and BAPA anticoagulated blood
2011
Clin Chem Lab Med
Szymezak J. et al.
High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment
2011
Thromb Res
Pettersen A. et al.
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
2011
Thrombosis Journal
Prüller F. et al.
Low platelet reactivity is recoverd by transfusion of stored platelets: A healthy volunteer in vivo study
2011
J Thromb Haemost
Wang XD. et al.
Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance
2011
Clin. Cardiol.
Frelinger A. et al.
Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications
2011
J. Am. Coll. Cardiol.
Angiolillo DJ et al.
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
2011
Thromb Haemost.
Storey RF et al.
Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses
2011
J Thromb Haemost
Fontana P et al.
Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study
2011
J Thromb Haemost
Fernando H et al.
Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel
2011
J Thromb Haemost
Bonello L et al.
High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes
2011
J. Am. Coll. Cardiol.
Ferreiro JL et al.
Pharmacodynamic evalutation of pentaprazole therapy on cloppidogrel effect
2011
Circ Cardiovasc Interv.
Ferreiro JL et al.
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
2011
Rev Esp Cardiol.
Ueno M et al.
Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
2011
J Am Coll Cardiol Intv
Bliden KP et al.
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies
2011
Am Heart J.
Grdinic A et al.
PCI and clopidogrel: antiplatelet responsiveness and patient characteristics
2011
Acta Cardiol.
Gaglia MA Jr et al.
Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity
2011
Am J Cardiol.
Mega J.L et al.
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
2011
JAMA
Tsoumani ME
Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate
2011
Angiology
Wang X.D et al.
Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance
2012
Eur J Int Med
Kobsar A et al.
The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets
2012
Thromb Haemost.
Jeong YH. et al.
High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?"
2012
J Thromb Haemost
Frelinger A.L. et al,
A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
2012
J. Am. Coll. Cardiol.
Reny J.L. et al.
Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis
2012
J Thromb Haemost
Tello-Montoliu A.et al.
Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy
2012
J. Am. Coll. Cardiol.
Ferreiro J.L.et al.
Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
2012
Rev Esp Cardiol.
Aradi D et al.
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity
2012
Eur J Clin Invest.
Yokoi H et al.
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention
2012
Thromb Res
Bonello L. et al
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel
2012
J Thromb Haemost
Liang Y et al
Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin
2012
J Thromb Thrombolysis
Bonello L. et al
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction
2012
Thromb Haemost.
Bonello L. et al
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade
2012
Thromb Res
Erlinge D. et al
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
2012
J Am Coll Cardiol
Suryadevara S. et al
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patientswith type 2 diabetes mellitus
2012
Thromb Haemost
Cuisset T. et al
CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome
2012
J Am Coll Cardiol Intv
Chang H et al
Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation
2012
J Thromb Haemost
Tello-Montoliu A et al
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus
2012
J Thromb Thrombolysis
Morel et al
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
2012
Thromb Haemost.
Grosdidier C et al.
Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
2013
Am J Cardiol.
Gremmel T et al.
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation
2013
Transl Res.
Frelinger A.L et al.
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F
2013
J Am Coll Cardiol
Gaglia MA et al.
Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity
2013
Cardiovasc Revasc Med.
Wun T et al.
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
2013
J Hematol Oncol.
Delavenne X et al.
Investigation of drug–drug interactions between clopidogrel and fluoxetine
2013
Fundam. Clin. Pharmacol.
Kerneis M et al.
Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel
2013
J Am Coll Cardiol Intv
Ferreiro JL et al.
Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy
2013
J Am Coll Cardiol
Mazur P. et al
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease
2013
Platelets
Nakata T et al
Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation
2013
Circ. J
Yano H et al
Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin
2012
Circ J.
Erlinge D. et al.
Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains noninferiority
2013
J Am Coll Cardiol
Laine M. et al.
Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention
2013
Thromb Res.
Kim I.S. et al.
Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in
2013
Am Heart J
El-Halabi MM et al.
CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Anti-Platelet Action of Clopidogrel
2013
J Cardiovasc Pharmacol.
Fontana P et al.
Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
2013
J Am Heart Assoc.
Gurbel PA et al.
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study
2013
J Am Coll Cardiol.
Gremmel T et al.
Response to antiplatelet therapy is independent of endogenous thrombin generation potential
2013
Thromb Res.
Tello-Montoliu M. et al.
Impact of aspirin dose on adenosine diphosphate-mediated platelet activity Results of an in vitro pilot investigation
2013
Thromb Haemost
Bonello L. et al.
A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity
2013
Int J Cardiol.
Cuisset T. et al
Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine
2013
J Am Coll Cardiol
Saucedo JF. et al
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching
2013
Thromb Haemost
Tantry U.S.
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
2013
J Am Coll Cardiol.
Aradi D et al
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
2014
Eur Heart J.
Laine M et al
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome
2014
Thromb Haemost
Darlington A et al
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery
2014
Thromb Haemost
Patel Y.M. et al
A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in PAR-1 in a patient with chronic bleeding
2014
J Thromb Haemost
Samoš M et al
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis
2014
Am J Emerg Med
Wisman P.P et al
Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and
2014
J Thromb Haemost
Lhermusier T et al
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
2014
J Interv Cardiol.
Jakubowski JA et al
The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.
2014
Thromb Res.
Timur AA, et al
Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
2014
Thromb Res.
Tang N et al.
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese
2015
Scand J Clin Lab Invest
Siller-Matula J. M. et al
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?
2015
Thromb Haemost
Aradi D. et al
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
2015
Eur Heart J
Danese E. et al
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
2015
J Thromb Haemost
Bagoly Z. et al
How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
2016
Platelets
Bonello L. et al
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective study
2015
Int J Cardiol
Danese E. et al
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
2016
J Thromb Haemost.
Storey R.F. et al
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
2016
J Am Coll Cardiol
Rollini F. et al
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors
2016
Thromb Haemost
Umemura K et al
Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
2016
Drug Metab Pharmacokinet
Franchi F. et al
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study
2016
Circulation
Umemura K et al
Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
2016
Drug Metab Pharmacokinet
Baumann M. et al.
The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration.
2021
Platelets